[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE270550T1 - Wirkstoff zum schutz für organ oder gewebe - Google Patents

Wirkstoff zum schutz für organ oder gewebe

Info

Publication number
ATE270550T1
ATE270550T1 AT96908342T AT96908342T ATE270550T1 AT E270550 T1 ATE270550 T1 AT E270550T1 AT 96908342 T AT96908342 T AT 96908342T AT 96908342 T AT96908342 T AT 96908342T AT E270550 T1 ATE270550 T1 AT E270550T1
Authority
AT
Austria
Prior art keywords
group
tissues
active substance
protect organs
organs
Prior art date
Application number
AT96908342T
Other languages
English (en)
Inventor
Mikio Ota
Hideki Horiuchi
Shigehisa Kitahara
Shiro Kondo
Yasuhiro Takano
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13778322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE270550(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Ltd filed Critical Teijin Ltd
Application granted granted Critical
Publication of ATE270550T1 publication Critical patent/ATE270550T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT96908342T 1995-04-07 1996-04-04 Wirkstoff zum schutz für organ oder gewebe ATE270550T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8257695 1995-04-07
PCT/JP1996/000924 WO1996031211A1 (fr) 1995-04-07 1996-04-04 Agent protecteur pour organe ou tissu

Publications (1)

Publication Number Publication Date
ATE270550T1 true ATE270550T1 (de) 2004-07-15

Family

ID=13778322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908342T ATE270550T1 (de) 1995-04-07 1996-04-04 Wirkstoff zum schutz für organ oder gewebe

Country Status (11)

Country Link
US (1) US5843969A (de)
EP (1) EP0779074B1 (de)
JP (1) JP3194964B2 (de)
KR (1) KR100308332B1 (de)
AT (1) ATE270550T1 (de)
AU (1) AU703609B2 (de)
CA (1) CA2190993C (de)
DE (1) DE69632854T2 (de)
ES (1) ES2224160T3 (de)
TW (1) TW425284B (de)
WO (1) WO1996031211A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2505690T3 (es) * 2002-03-28 2014-10-10 Teijin Pharma Limited Preparación sólida que contiene una forma única de cristal de un derivado de ácido tiazolcarboxílico
EP1783124A4 (de) * 2004-08-27 2009-07-08 Astellas Pharma Inc 2-phenylthiophenderivat
JP4894517B2 (ja) * 2004-08-27 2012-03-14 アステラス製薬株式会社 2−フェニルピリジン誘導体
US8841333B2 (en) 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
CN101282934A (zh) 2005-10-07 2008-10-08 安斯泰来制药株式会社 三芳基羧酸衍生物
CA2643272A1 (en) 2006-02-24 2007-08-30 Astellas Pharma Inc. Gent for treating or preventing digestive ulcer
WO2008010315A1 (fr) * 2006-07-19 2008-01-24 Nippon Medical School Foundation Agent thérapeutique destiné à la sclérose latérale amyotrophique
KR20090103879A (ko) * 2006-11-13 2009-10-01 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
SG186301A1 (en) 2010-06-16 2013-02-28 Takeda Pharmaceuticals Usa Inc Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
RU2013109380A (ru) 2010-09-10 2014-10-20 Такеда Фармасьютикалс Ю.С.А.,Инк. Способ сопутствующей терапии с применением теофиллина и фебуксостата
TW201328692A (zh) * 2011-10-11 2013-07-16 Univ Osaka 脫髓鞘疾病之治療劑及預防劑
EP2692342A1 (de) 2012-07-30 2014-02-05 Interquim, S.A. Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Febuxostat in Tablettenform
CN103848798B (zh) 2012-11-30 2016-01-06 镇江新元素医药科技有限公司 2-芳基硒唑化合物及其药物组合物
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
CA2955485A1 (en) 2014-07-30 2016-02-04 Teijin Pharma Limited Crystal of azole benzene derivative
JP6134072B2 (ja) * 2014-07-30 2017-05-24 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬
ME03319B (de) * 2014-07-30 2019-10-20 Teijin Pharma Ltd Azolbenzolderivat und kristall daraus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009381A1 (en) * 1989-02-08 1990-08-23 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
JP2665564B2 (ja) * 1989-08-25 1997-10-22 株式会社大塚製薬工場 細胞防護剤
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
JPH04117371A (ja) * 1990-09-05 1992-04-17 Otsuka Pharmaceut Factory Inc チアゾール誘導体
JP2725886B2 (ja) * 1990-11-30 1998-03-11 帝人株式会社 2―アリールチアゾール誘導体及びその医薬組成物
CA2122596C (en) * 1991-10-31 2008-06-03 Nancy Jane Rothwell Treatment of neurological conditions by an interleukin-1 inhibiting compound
JPH05320072A (ja) * 1992-05-20 1993-12-03 Taiho Yakuhin Kogyo Kk 虚血性脳疾患治療薬

Also Published As

Publication number Publication date
EP0779074A1 (de) 1997-06-18
EP0779074A4 (de) 1999-06-30
DE69632854T2 (de) 2005-07-14
JP3194964B2 (ja) 2001-08-06
CA2190993A1 (en) 1996-10-10
TW425284B (en) 2001-03-11
AU703609B2 (en) 1999-03-25
KR100308332B1 (ko) 2002-09-17
CA2190993C (en) 2004-06-01
ES2224160T3 (es) 2005-03-01
WO1996031211A1 (fr) 1996-10-10
DE69632854D1 (de) 2004-08-12
AU5162396A (en) 1996-10-23
EP0779074B1 (de) 2004-07-07
US5843969A (en) 1998-12-01

Similar Documents

Publication Publication Date Title
ATE270550T1 (de) Wirkstoff zum schutz für organ oder gewebe
NO970892L (no) Isoksazolderivater
CA2113229A1 (en) Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
NO992336L (no) Raf-kinase-inhibitorer
NO903438L (no) Fremgangsmaate for fremstilling av tiazolderivater.
MX9800577A (es) Derivados de 4,5-diaril oxazol.
BG104853A (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
BR1100636A (pt) Agente terapêutico para o mal de parkinson, e, derivado da xantina
WO2001012169A3 (en) Method of cancer treatment
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
IT1196423B (it) Benzotiazolin-composti
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
DE69518706D1 (de) Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom
ES2096208T3 (es) Derivados de octahidronaftaleno oxima para la inhibicion de la biosintesis de colesterol, su preparacion y utilizacion.
FR2869316A1 (fr) Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
DK0413278T3 (da) Anvendelse af xanthinderivater mod mavesår
DE69532963D1 (de) Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen
TH31635A (th) อนุพันธ์คาร์โบไฮเดรต
DE69424677D1 (de) Präparat zur behandlung der drogenabhängigkeit
TH20908B (th) อนุพันธ์คาร์โบไฮเดรต
RU94038051A (ru) Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0779074

Country of ref document: EP